Symbicort® Turbuhaler® (budesonide/formoterol delivered via the inhaler device, Turbuhaler®) is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid [ICS] and long-acting β2 adrenoceptor agonist [LABA]) is appropriate:
- patients not adequately controlled with ICS and “as needed” inhaled short-acting β2 adrenoceptor agonists (SABAs).
- patients already adequately controlled on both ICS and LABAs [1,2,3].
Symbicort® is also widely used as inhaled medication for COPD (Read about Symbicort® in COPD).
In asthma, Symbicort® is licensed for use as a regular maintenance therapy with a separate SABA as needed or as a maintenance and reliever therapy in one inhaler, Symbicort® Maintenance And Reliever Therapy (Symbicort Turbuhaler SMART™); both fixed maintenance and maintenance plus as needed doses are recommended by the GINA 2014 report . Symbicort Turbuhaler SMART™ combines the anti-inflammatory corticosteroid budesonide and the rapid and long-lasting bronchodilator formoterol in one combination inhaler, to provide an effective approach to managing asthma [5–11]. This approach uses the same Symbicort® inhaler for both maintenance and relief.
Read more about the mechanism of action of budesonide and formoterol
SEE YOUR LOCAL COUNTRY SYMBICORT® PRODUCT INFORMATION BECAUSE PRESCRIBING INFORMATION MAY VARY FROM COUNTRY TO COUNTRY.
With Symbicort Turbuhaler SMART™, patients take a maintenance dose of Symbicort® in line with normal practice to establish asthma control and take additional inhalations of Symbicort® as needed if symptoms occur, to provide rapid symptom relief and increased asthma control.
With this approach, the underlying inflammation is treated with every inhalation , making it a more effective treatment approach than traditional ICS and ICS/LABA maintenance therapies using a SABA as needed, improving daily symptom control and reducing asthma attacks [5–10]. Read more about clinical efficacy of Symbicort®. Symbicort Turbuhaler SMART™ is also a simpler regimen since a separate short-acting bronchodilator is no longer needed.
The concept behind Symbicort Turbuhaler SMART™ is to treat the inflammation with every inhalation, whether used for maintenance or relief [8, 13]
Symbicort Turbuhaler SMART™ (budesonide/formoterol maintenance and reliever therapy) is an asthma medication that combines budesonide, an ICS that provides an anti-inflammatory effect, with formoterol, a rapid LABA bronchodilator, in a single inhaler for both maintenance and reliever therapy for the treatment of asthma. Symbicort Turbuhaler SMART™ treats the inflammation associated with asthma with every inhalation and thus reduces symptoms and the risk of exacerbations [5, 6, 9, 10].
Symbicort Turbuhaler SMART™ treats inflammation and reduces symptoms and exacerbations with extra as needed doses *
*Postulated mechanism of action as suggested
AstraZeneca monitors the safety of our products by collecting, evaluating and reporting adverse events/side effects from a variety of sources. This is a critical component in the development of the prescribing information that provides healthcare professionals with the benefit/risk information they need to make appropriate prescribing decisions.
Countries worldwide may have specific processes in place to handle reports of adverse events. Please refer to the manufacturer contact information contained in the prescribing information to report any adverse events/side effects experienced by patients while taking an AstraZeneca prescription drug.